513 - Blockage of IL-25 pathway as a potential target therapy for atopic dermatitis

特应性皮炎 医学 皮肤病科 免疫学
作者
Thomas Chin Wai Hui,Lik Hang Lam,Weimin Li,Kai Cheung Chow,Shui On Leung
出处
期刊:British Journal of Dermatology [Oxford University Press]
卷期号:190 (Supplement_2): ii17-ii17 被引量:2
标识
DOI:10.1093/bjd/ljad498.020
摘要

Abstract Introduction Interleukin 25 (IL-25) is an alarmin that binds to its receptor composed of IL-17RA and IL-17RB and is known to induce the production of type 2 cytokines, leading to T helper type 2 (Th2) inflammatory responses. Atopic dermatitis (AD) is an autoimmune and chronic disorder that causes inflammation, dryness, redness and irritation of the skin. It is well-­documented that upregulated IL-25 expression is tightly correlated with the disease severity of AD patients, suggesting that the IL-25 pathway is a potential therapeutic target of AD. SM17 is a humanized antibody of the IgG4/kappa isotype targeting the IL-25 pathway via specific binding to IL-17RB, a co-receptor for IL-25 expressed on the surface of ILC2 cells, dendritic Cells, fibroblast and epithelial cells. Therefore, we hypothesize that SM17 might serve as a potential therapeutic treatment for AD. Objectives The current study aims at investigating if blockage of IL-25 pathway through SM17 administration could ameliorate AD associated inflammation, skin pathology and pruritus. Methods To provide first evidence that SM17 could improve skin conditions, PBMCs from healthy individuals were pretreated with a cocktail of alarmins comprising IL-25, IL-33, and TSLP with or without SM17, and the mixture was co-cultured with the fully differentiated human keratinocyte cell line HaCaT in a transwell system for five days. Filaggrin level in HaCaT cells was used as an indicator for skin health. Beneficial effects of SM17 in AD was further tested in the 1-Fluoro-2,4-dinitrobenzene (DNFB) induced AD mouse model. DNFB and SM17 were administrated to the animals once per week and tissues were harvested after a month. Single cells were isolated from submental lymph nodes for ex-vivo culture while both dorsal skin and ear were collected for histological and biochemical analyses. In vivo efficacy of SM17 was further compared with upadacitinib, a JAK1 inhibitor currently approved by the FDA for the treatments of adults and adolescents aged 12+ years with moderate to severe AD, via behavioral, histological and biochemical analyses. Results We first demonstrated that SM17 could potentially ameliorate the skin condition by upregulating the filaggrin levels in keratinocyte during Th2 inflammatory responses in vitro. In the DNFB induced AD mouse model, SM17 could improve the skin conditions in both ear and dorsal skin through attenuation of Th2 cytokine levels in submental lymph node and skin samples, and reduce infiltration of mast cell and eosinophil, while upregulating filaggrin expression in the skin layer. Weekly administration of SM17 provided similar efficacy as upadacitinib (5 doses/week) to suppress DNFB induced scratching behavior, thickening of skin and ear, and global induction of Th2 inflammatory responses in multiple tissues. Conclusions In summary, these in vitro and in vivo data indicate that blockade of IL-25 pathway by SM17 could suppress Th2 mediated inflammatory response and ameliorate the AD pathology similar to that of upadacitinib, probably with a superior safety profile as demonstrated in our Phase I clinical trial (ClinicalTrials.gov Identifier: NCT05332834), where good safety profile and tolerability were observed with no reported cases of severe TEAE. We believe that SM17 could serve as a potential therapeutic treatment for AD in the future.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
黄少年完成签到,获得积分10
1秒前
好眠哈密瓜完成签到 ,获得积分10
1秒前
玛玛哈哈发布了新的文献求助10
2秒前
Owen的应助被感动的易真采纳,获得10
2秒前
白白完成签到,获得积分10
2秒前
3秒前
3秒前
3秒前
盈虚者发布了新的文献求助10
3秒前
MzzzzX完成签到 ,获得积分10
4秒前
小彦发布了新的文献求助10
7秒前
情怀的应助被白玄采纳,获得10
7秒前
爆米花的应助被痕墨笙采纳,获得10
9秒前
科研通AI2S的应助被王蕊采纳,获得10
9秒前
adden发布了新的文献求助10
10秒前
10秒前
10秒前
11秒前
小蘑菇的应助被丙烯酸树脂采纳,获得10
11秒前
11秒前
11秒前
12秒前
12秒前
迷你的外套完成签到,获得积分10
13秒前
深情安青的应助被花花采纳,获得10
13秒前
哭泣FF完成签到,获得积分10
13秒前
顾玖发布了新的文献求助10
16秒前
16秒前
嘻嘻哈哈发布了新的文献求助310
16秒前
一块麻糖发布了新的文献求助10
16秒前
调皮的洪金宝完成签到,获得积分10
16秒前
青山发布了新的文献求助10
17秒前
17秒前
18秒前
Xijizyx完成签到,获得积分10
18秒前
搞怪雨琴发布了新的文献求助10
19秒前
zhangzhangZZZ发布了新的文献求助10
19秒前
zxh完成签到,获得积分10
20秒前
21秒前
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158056
求助须知:如何正确求助?哪些是违规求助? 9553944
关于积分的说明 21716733
捐赠科研通 7747388
什么是DOI,文献DOI怎么找? 3426934
关于科研通互助平台的介绍 2551676
邀请新用户注册赠送积分活动 2471038